Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of lactobacillus reuteri in preventing and relieving ulcerative colitis

A technology of Lactobacillus reuteri and ulcerative colitis, applied in the field of functional microorganisms, to achieve the effect of improving colonic mucosal damage, reducing relative abundance, and good tolerance

Active Publication Date: 2021-04-13
JIANGNAN UNIV
View PDF2 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are no related probiotics that can play a good role in prevention, regulation or treatment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of lactobacillus reuteri in preventing and relieving ulcerative colitis
  • Application of lactobacillus reuteri in preventing and relieving ulcerative colitis
  • Application of lactobacillus reuteri in preventing and relieving ulcerative colitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0053] Example 1: Lactobacillus reuteri CCFM1135 has good tolerance to simulated gastrointestinal fluid

[0054] Inoculate cryopreserved Lactobacillus reuteri CCFM1135 in mMRS medium, culture anaerobically at 37°C for 48 hours, and subculture 2 to 3 times in mMRS medium, take 1 mL of Lactobacillus reuteri CCFM1135 culture medium , mixed with 9.0mL pH 2.5 artificial simulated gastric juice (mMRS medium containing 1% pepsin, pH = 2.5), and anaerobically cultured at 37°C, samples were taken at 0h, 0.5h, 1h, 2h and 3h, and used The mMRS agar medium was poured and cultured for plate colony counting, the number of viable bacteria was determined and the survival rate was calculated (see Table 1).

[0055] Take 1 mL of the culture solution of Lactobacillus reuteri CCFM1135 and add it to 9 mL of artificial simulated intestinal fluid (mMRS medium containing 0.3% bovine bile salt, 1% trypsin, pH=8.0), and culture it anaerobically at 37°C. , 0.5h, 1h, 2h, 3h and 4h, take samples, use mMR...

Embodiment 2

[0061] Example 2: Lactobacillus reuteri CCFM1135 has no toxic side effects on C57BL / 6J mice

[0062] Resuspend Lactobacillus reuteri CCFM1135 in 3mg / 100mL (w / v) sucrose solution to make a concentration of 5.0×10 9 CFU / mL bacterial suspension. Take 6 healthy male C57BL / 6J mice with a body weight of about 14-16g. After adapting to the environment for a week, they are given the bacterial suspension of this concentration by gavage once a day (0.2mL per gavage), observed for a week, and recorded the death and body weight. .

[0063] The results of these tests are listed in Table 3. These results indicated that feeding concentrations of 5.0×10 9 CFU / mL of Lactobacillus reuteri CCFM1135 had no significant impact on mice, no significant change in body weight, and no death. The appearance of the mice had no obvious pathological symptoms.

[0064] Table 3 Changes in body weight and death of mice

[0065] time (days) 1 2 3 4 5 6 7 weight(g) 20.13±0.42 20.42±...

Embodiment 3

[0067] Example 3: Effect of Lactobacillus reuteri CCFM1135 on disease symptoms in UC mice

[0068] Take 30 healthy male C57BL / 6J mice weighing 14-16g, adapt to the environment for 1 week, 6 mice in each group, and randomly divide them into 5 groups: blank group, model group, drug group, Lactobacillus reuteri CCFM1135 intervention group (CCFM1135), Lactobacillus reuteri FCQHC8L6 control group (FCQHC8L6). The dose of intragastric bacterial suspension was 5.0×10 9 CFU / mL, resuspended in 3% (w / v) sucrose solution, orally administered 0.2 mL per day. In the fifth week, 2.5% (w / v) dextran sodium sulfate (dextransulphate sodium, DSS) was added to drinking water for 7 days to induce colitis in mice. The grouping and treatment methods of the experimental animals are shown in Table 4.

[0069] Table 4 Animal experiment design

[0070]

[0071]

[0072] In the fifth week, that is, during the modeling period (DSS treatment), the body weight of the mice was regularly weighed ever...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of lactobacillus reuteri in preventing and relieving ulcerative colitis, and belongs to the technical field of functional microorganisms. Lactobacillus reuteri CCFM1135 can tolerate the gastrointestinal environment of a human body, significantly reduce the disease activity index during the ulcerative colitis, improve colon mucosal injury, reduce MPO activity, reduce the content of proinflammatory factors TNF-alpha, IL-6 and IFN-gamma in colon, up-regulate the transcription level of colon tight junction related proteins Claudin-3, ZO-1, ZO-2 and Occludin, up-regulate the transcription levels of colon antibacterial peptides Reg3g and Reg3b, improve the diversity of intestinal flora, and reduced the relative abundance of acinetobacter in excrement.

Description

technical field [0001] The invention relates to the application of a strain of Lactobacillus reuteri in preventing and alleviating ulcerative colitis, and belongs to the technical field of functional microorganisms. Background technique [0002] Inflammatory bowel disease (Inflammatory bowel disease, IBD) is a recurrent gastrointestinal disease. Inflammatory bowel disease has an unknown etiology, long course of disease, easy recurrence, many complications and difficult to cure. Ulcerative colitis (UC) is a type of inflammatory bowel disease, the main clinical manifestations are chronic or subacute diarrhea, mucus pus and blood in the stool and abdominal pain. UC is a continuous inflammation of colonic mucosa and submucosa, and the disease usually starts from the rectum and spreads to the whole colon. UC began in western countries. In recent decades, with economic development, UC has also appeared in undeveloped regions such as Asia, South America and the Middle East. Now U...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12N1/20C12N1/04A61K35/747A61P1/00A23C9/123A23C13/16A23C19/00A23L11/50A23L19/00A23L19/10C12R1/225
CPCC12N1/20C12N1/04A61K35/747A61P1/00A23C9/1234A23C13/16A23C19/00A23L19/00A23L19/10A23V2002/00A23V2400/173A23V2200/3204Y02A50/30
Inventor 王刚郑雨星王琳琳赵建新张灏陈卫
Owner JIANGNAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com